NCT00825500View on ClinicalTrials.gov

Staccato Loxapine in Migraine (Out Patient)

PHASE2CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Migraine Headache
Interventions
DRUG

Inhaled Placebo

Inhaled Staccato placebo (0 mg)

DRUG

Inhaled Loxapine 1.25 mg

Inhaled Staccato Loxapine 1.25 mg, single dose

DRUG

Inhaled Loxapine 2.5 mg

Inhaled Staccato Loxapine 1.25 mg, single dose

Trial Locations (3)

10550

Elkind Headache Center, Mount Vernon

65807

Roger K. Cady, Springfield

02916

CNS Research, Inc., East Providence

Sponsors
All Listed Sponsors
lead

Alexza Pharmaceuticals, Inc.

INDUSTRY

NCT00825500 - Staccato Loxapine in Migraine (Out Patient) | Biotech Hunter | Biotech Hunter